Osteocis (Sodium Oxidronate)

Sodium Oxidronate, the active ingredient in Osteocis, is a bisphosphonate presented as an intravenous solution for parenteral use. It treats osteoporosis and related bone mineral density disorders in adults. GNH USA supplies Osteocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Osteocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osteocis is a bisphosphonate indicated for disorders affecting the skeletal system where bone resorption is increased.

- Osteoporosis: improves bone mineral density and reduces fracture risk. - Paget's disease of bone: normalises abnormal bone remodeling. - Hypercalcaemia of malignancy: lowers elevated serum calcium levels. - Bone metastases associated with solid tumours: helps control skeletal‑related events. - Osteogenesis imperfecta: increases bone strength in selected cases. - Steroid‑induced osteoporosis: mitigates bone loss due to long‑term glucocorticoid therapy.

Sodium Oxidronate may cause a range of adverse reactions, most of which are dose‑dependent and related to its action on bone metabolism.

Common Side Effects: - Flu‑like symptoms: fever, chills, myalgia. - Musculoskeletal pain: bone, joint or muscle discomfort. - Nausea or vomiting. - Transient elevation of serum creatinine. - Injection site reactions: erythema or swelling.

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ). - Atypical femoral fractures. - Severe renal impairment. - Hypocalcaemia. - Acute phase reactions with severe fever. - Anaphylactic or severe allergic reactions.

Before                              ​   ​        ​    ​          ​      ​ ​       ​               ​        ​ ​   “         …   …  …  “    “  …  …  “  …  “  “  …  …  …  “  … …  “  …  “  </     "    “  …  “ bullet   “ …  “ … … …  “ …  “ …  ...